Analytical Data
-
基因名
PP13
- Application
-
别名
LGALS13; PLAC8; PP13; GAL13; Galectin 13; Galactoside-Binding Soluble Lectin 13; Placental tissue protein 13
-
种属
Human
-
表达系统
E. coli
-
标签
N- His & GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UHV8
-
表达区间
Met1~Asn139
-
分子量
44kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PP13, a member of the pregnancy-specific glycoprotein family, has garnered significant interest in recent years due to its potential role in reproductive biology and immunology. This protein is predominantly expressed in the placenta during gestation, suggesting it may play a pivotal role in maternal-fetal interaction and immune tolerance. Studies have shown that PP13 can modulate maternal immune responses, potentially influencing pregnancy outcomes and the development of pregnancy-related complications such as preeclampsia. Moreover, its unique expression pattern makes PP13 a candidate for investigating biomarkers for early pregnancy complications and for developing therapeutic interventions. Recent advancements in recombinant protein technology have facilitated the production of PP13, allowing researchers to explore its structural and functional properties in depth. Understanding the mechanisms underlying PP13's activity could provide valuable insights into its role in placentation and immune modulation, which may lead to significant advancements in maternal-fetal medicine and improved management of pregnancy-related disorders. As research progresses, the comprehensive characterization of the PP13 protein and its interactions within the maternal environment will be crucial for delineating its biological significance and potential clinical applications.
